This study compared the carbon footprint of SC and IV administration using pertuzumab/trastuzumab as a case example. A Life Cycle Assessment was conducted to compare the environmental impacts of IV ...

Trastuzumab, tested only as a single agent, has been shown to achieve 7% response in heavily pretreated patients with AOC with 3+ and 2+ HER2 immunostaining by immunohistochemistry (IHC).